Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CODIAK BIOSCIENCES, INC.

(CDAK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
12.53(c) 12.75(c) 12.47(c) 13.04(c) 12.2(c) Last
42 059 45 705 53 830 48 869 49 207 Volume
-5.72% +1.76% -2.20% +4.57% -6.44% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 17,5 M - -
Net income 2021 -74,6 M - -
Net Debt 2021 - - -
P/E ratio 2021 -3,57x
Yield 2021 -
Sales 2022 6,22 M - -
Net income 2022 -90,3 M - -
Net Debt 2022 - - -
P/E ratio 2022 -3,68x
Yield 2022 -
Capitalization 273 M 273 M -
Capi. / Sales 2021 15,6x
Capi. / Sales 2022 43,8x
Nbr of Employees 105
Free-Float 99,9%
More Financials
Company
Codiak BioSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of exosome-based therapeutics. The Company has developed its engineering and manufacturing platform, engEx Platform, to develop upon the innate properties of exosomes to design, engineer and manufacture exosome therapeutics. It utilizes the engEx Platform to generate a pipeline of engineered exosomes... 
More about the company
Ratings of Codiak BioSciences, Inc.
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about CODIAK BIOSCIENCES, INC.
12/02Codiak BioSciences Says Its COVID-19 Vaccine Candidate Shows Evidence of Activity Again..
MT
12/02Codiak's Engineered Exosomes Promote T Cell and Antibody Responses to SARS-CoV-2 in viv..
GL
12/02Codiak?S Engineered Exosomes Promote T Cell and Antibody Responses to Sars-Cov-2 in Viv..
CI
12/01Codiak BioSciences to Present at the 4th Annual Evercore ISI HealthCONx Conference
GL
11/30Codiak BioSciences Says FDA Accepts Investigational New Drug Application for exoASO-STA..
MT
11/30Codiak BioSciences Gets FDA Approval for ExoASO-STAT6 IND Application
DJ
11/30CODIAK BIOSCIENCES : Announces FDA Clearance of IND for exoASO™-STAT6; Patient Dosing..
PU
11/30CODIAK BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (fo..
AQ
11/30Codiak BioSciences Announces FDA Clearance of IND for exoASO™-STAT6; Patient Dosi..
AQ
11/30Codiak Biosciences Announces FDA Clearance of IND for exoASO?-STAT6; Patient Dosing Exp..
CI
11/17CODIAK BIOSCIENCES : Reports Positive Initial Data for exoSTING™ Phase 1/2 Trial Indi..
PU
11/17CODIAK BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (fo..
AQ
11/16CODIAK BIOSCIENCES, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
11/16Codiak Reports Positive Initial Data for exoSTING™ Phase 1/2 Trial Indicating Tol..
GL
11/16Codiak Reports Positive Initial Data for exoSTING™ Phase 1/2 Trial Indicating Tol..
GL
More news
News in other languages on CODIAK BIOSCIENCES, INC.
12/02Codiak BioSciences affirme que son vaccin candidat COVID-19 présente des signes d'activ..
11/05Codiak BioSciences dépose une demande d'émission d'un maximum de 300 millions de dollar..
11/04Earnings Flash (CDAK) CODIAK BIOSCIENCES affiche un chiffre d'affaires de 1,16 million ..
11/02KORR : Lonza übernimmt zwei Spezialisten für Proteinkomplexe
11/02Codiak BioSciences vend son usine de fabrication d'exosomes à Lonza
More news
Analyst Recommendations on CODIAK BIOSCIENCES, INC.
More recommendations
Chart CODIAK BIOSCIENCES, INC.
Duration : Period :
Codiak BioSciences, Inc. Technical Analysis Chart | CDAK | US1920101060 | MarketScreener
Technical analysis trends CODIAK BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 12,20 $
Average target price 39,50 $
Spread / Average Target 224%
EPS Revisions
Managers and Directors
Douglas E. Williams President, Chief Executive Officer & Director
Linda C. Bain Chief Financial Officer & Treasurer
Steven H. Gillis Chairman
Konstantin Konstantinov Chief Technology Officer
Jennifer Wheler Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
CODIAK BIOSCIENCES, INC.-61.39%273
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-41.36%24 298